Hypermethylation downregulates P2X₇ receptor expression in astrocytoma

Area of Science:

• Neuroscience
• Molecular Biology
• Oncology

Background:

• Astrocytoma is a primary brain tumor with varying grades of malignancy.
• The role of specific purinergic receptors, like P2X7 receptor (P2X₇R), in astrocytoma pathogenesis is not fully understood.

Purpose of the Study:

• To investigate the expression levels of P2X7 receptor (P2X₇R) in astrocytoma.
• To explore the correlation between P2X₇R expression and astrocytoma malignancy.
• To determine the potential mechanisms, such as DNA methylation, underlying altered P2X₇R expression in astrocytoma.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot to assess P2X₇R mRNA and protein levels.
• DNA methylation analysis of the P2X₇R gene promoter using Sequenom MassARRAY.
• Immunohistochemistry (IHC) to evaluate P2X₇R expression across different astrocytoma grades (diffuse astrocytoma, anaplastic astrocytoma, glioblastoma).

Main Results:

• P2X7 receptor (P2X₇R) mRNA and protein expression were significantly reduced in glioblastoma (GBM) compared to normal brain tissue.
• Immunohistochemistry revealed a negative correlation between P2X₇R expression levels and astrocytoma tumor grade.
• Hypermethylation of the P2X₇R gene promoter was identified as a primary mechanism contributing to the decreased P2X₇R expression in GBM.

Conclusions:

• P2X7 receptor (P2X₇R) expression is downregulated in astrocytoma, particularly in higher-grade tumors like glioblastoma.
• Promoter hypermethylation is a key factor in the reduced expression of P2X₇R during astrocytoma progression.
• These findings highlight the significant role of P2X₇R in astrocytoma tumorigenesis and progression, suggesting its potential as a therapeutic target.